


|  |  |   |  |  |  |
|--|--|---|--|--|--|
| FORM PTO-1390<br>(REV. 11-2000) modified   |  | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE |  | AGENT'S DOCKET NUMBER<br><div style="font-size: 1.5em; font-weight: bold;">68 USOP</div>                             |  |
| <b>TRANSMITTAL LETTER TO THE UNITED STATES<br/>DESIGNATED/ELECTED OFFICE (DO/EO/US)<br/>CONCERNING A FILING UNDER 35 U.S.C. 371</b>  |  |   |  | U.S. APPLICATION NO. (If known, see 37 CFR 1.5)<br><div style="font-size: 1.5em; font-weight: bold;">10/088771</div> |  |
| INTERNATIONAL APPLICATION NO.<br><b>PCT/JP00/06375</b>   |  | INTERNATIONAL FILING DATE<br><b>September 19, 2000</b>  |  | PRIORITY DATE CLAIMED<br><b>September 20, 1999</b>   |  |
| TITLE OF INVENTION<br><b>Melanin Concentrating Hormone Antagonist</b>  |  |   |  |  |  |
| APPLICANT(S) FOR DO/EO/US<br><b>Kaneyoshi KATO, Jun TERAUCHI, Masaaki MORI, Nobuhiro SUZUKI, Yukio SHIMOMURA, Shiro TAKEKAWA, Yuji ISHIHARA</b>  |  |   |  |  |  |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:  |  |   |  |  |  |
| <ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).           <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol> <p><b>Items 11 to 20 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>20. <input checked="" type="checkbox"/> Other items or information:           <div style="display: flex; justify-content: space-between; margin-top: 5px;"> <div>             Itemized Return Postcard; Certificate of Express Mailing;<br/>             PCT Forms 101, 301, 304, 308, 332; Written Opinion;<br/>             Recordation Cover Sheet; Cited References (15)           </div> <div>             Express Mail Label No. EL 916492917 US<br/>             Date of Deposit <b>March 19, 2002</b> </div> </div> </li> </ol> |  |   |  |  |  |

|   |              |   |            |  |    |           |  |    |  |
|---|--------------|---|------------|--|----|-----------|--|----|--|
| U.S. APPLICATION NO. (if known, see 37 CFR 1.53)<br><b>10/0887</b>  |              | INTERNATIONAL APPLICATION NO.<br>PCT/JP00/06375 |            | ATTORNEY'S DOCKET NUMBER<br>2648 USOP  |    |           |  |    |  |
| 21. <input checked="" type="checkbox"/> The following fees are submitted:<br><b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b><br>Neither international preliminary examination fee (37 CFR 1.482)<br>nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO<br>and International Search Report not prepared by the EPO or JPO. .... \$1040.00<br><br>International preliminary examination fee (37 CFR 1.482) not paid to<br>USPTO but International Search Report prepared by the EPO or JPO ..... \$890.00<br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO<br>but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00<br><br>International preliminary examination fee (37 CFR 1.482) paid to USPTO<br>but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$710.00<br><br>International preliminary examination fee (37 CFR 1.482) paid to USPTO<br>and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00<br><br><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b> |              |   |            | <b>CALCULATIONS PTO USE ONLY</b><br><br><br><br><br><br><br><br><br><br><table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: right;">\$ 890.00</td> <td style="width: 50%;"></td> </tr> <tr> <td style="text-align: right;">\$</td> <td></td> </tr> </table> |    | \$ 890.00 |  | \$ |  |
|   |              |   |            | \$ 890.00  |    |           |  |    |  |
| \$  |              |   |            |  |    |           |  |    |  |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).   |              |   |            | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: right;">\$</td> <td style="width: 50%;"></td> </tr> </table>  |    | \$        |  |    |  |
| \$  |              |   |            |  |    |           |  |    |  |
| CLAIMS  | NUMBER FILED | NUMBER EXTRA                                    | RATE       |  |    |           |  |    |  |
| Total claims  | 33 - 20 =    | 13  | x \$18.00  | \$ 234.00  |    |           |  |    |  |
| Independent claims  | 10 - 3 =     | 7   | x \$84.00  | \$ 588.00  |    |           |  |    |  |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable)   |              |   | + \$280.00 | \$   |    |           |  |    |  |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>  |              |   |            | \$   |    |           |  |    |  |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.  |              |   |            | \$   |    |           |  |    |  |
| <b>SUBTOTAL =</b>   |              |   |            | \$ 1,712.00  |    |           |  |    |  |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).  |              |   |            | \$   |    |           |  |    |  |
| <b>TOTAL NATIONAL FEE =</b>   |              |   |            | \$ 1,712.00  |    |           |  |    |  |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +  |              |   |            | \$   |    |           |  |    |  |
| <b>TOTAL FEES ENCLOSED =</b>  |              |   |            | \$ 1,712.00  |    |           |  |    |  |
|   |              |   |            | Amount to be refunded:   | \$ |           |  |    |  |
|   |              |   |            | charged:   | \$ |           |  |    |  |
| a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.<br>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>500799</u> in the amount of \$ <u>1,712.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.<br>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>500799</u> . A duplicate copy of this sheet is enclosed.<br>d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.  |              |   |            |  |    |           |  |    |  |
| <b>NOTE:</b> Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.   |              |   |            |  |    |           |  |    |  |
| SEND ALL CORRESPONDENCE TO:<br>Mark Chao, PhD, JD<br>Takeda Pharmaceuticals North America, Inc.<br>Suite 500, 475 Half Day Road<br>Lincolnshire, IL 60069 USA<br>(847)383-3372 fax (847)383-3481  |              |   |            |  |    |           |  |    |  |
|   |              |   |            | <br>SIGNATURE<br>Mark Chao, PhD, JD<br>NAME<br>37,293<br>REGISTRATION NUMBER<br>For Customer No. 23,115  |    |           |  |    |  |